Curanex Pharmaceuticals Inc

For the period ended Sep 30, 2025. Filed Nov 17, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 17, 2025

CURX$6.20-0.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Cash Flows

	For the Nine Months Ended September 30,
2025 · 2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss for the period		$(1,151,988)	$(215,567)
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Amortization of right-of-use assets		45,102	-
Changes in operating assets and liabilities:
Prepaid expenses		(8,586,042)	-
Lease liabilities		(44,350)	-
Accounts payable		109,489	5,000
Accrued expenses		741	(10,094)
Other current assets		-	(239,487)
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES		(9,627,048)	(460,148)
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of common stock		-	630,000
Issuance of preferred stock		-	100
Proceeds from issuance of common stock, net of underwriting costs		15,655,192	-
Payment offering costs		(346,497)	-
NET CASH PROVIDED BY FINANCING ACTIVITIES		15,308,695	630,100
NET INCREASE (DECREASE) IN CASH		5,681,646	169,951
Cash at beginning of period		148,891	74,366
CASH AT END OF PERIOD		$5,830,537	$244,317
Supplemental schedule of cash flow information:
Non-cash investing & financing activities:
Issuance of common stock with a non-cash payment	$	-	$100,000
Recognition of right-of-use asset in exchange for lease liability		105,501	-

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.